"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.World Economyread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
On Sunday, the 71st Primetime Emmy Awards will honor the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
"This would be the most profound violation of the presidential oath of office certainly during this presidency," House Intelligence Chair Adam Schiff said.Politicsread more
Globalization is a central feature in Takeda Pharmaceutical's strategy to achieve growth, the company's CEO told CNBC on Tuesday.
"The key for us is to globalize our key products and globalize the company. So instead of launching a new product in two countries, in three countries, we are launching these products globally. That's very key to growth in the future," Takeda Pharmaceutical President and CEO Christophe Weber said.
Weber also said the company's strategy to succeed in the increasingly competitive pharmaceutical space has been to be more innovative, adding that Takeda only develops medicine that has "high innovation potential."
"[We are] always looking for highly innovative medicine. That's really important because we don't want to develop medicine that isn't truly innovative," said Weber.
The company, he said, is currently focused on three therapy areas: gastroenterology, oncology and the central nervous system.
Takeda's first non-Japanese head, Weber has been under pressure to improve profitability at the pharmaceutical company. The push for internationalization has been part of the CEO's plans to turn things around at the Japanese pharma giant.
Takeda's consolidated net profit came in at 114.9 billion yen ($1.05 billion) for the year that ended on Mar. 31. In comparison, Astellas Pharma, a younger Japanese competitor, achieved double the profit despite lower sales, Nikkei Asian Review reported.
The company has forecast that its operating profit will rise 15.5 percent to 180 billion yen ($1.65 billion) this financial year compared to one year ago. Still, full-year guidance from Takeda remained below the average analyst estimate of 197.7 billion yen in a Thomson Reuters poll.
While Japanese companies have traditionally struggled to diversify and internationalize, Weber's push for globalization can be seen within the 235-year-old company. Three out of Takeda's four inside directors are not Japanese, Nikkei said.
Takeda currently concentrates its research and development in the U.S. and Japan. Weber said the best way to ensure that teams in both countries work well together was to facilitate employee "exchange."
"We are glad to see so many Japanese [employees] moving to Boston, but we also want our researchers in Boston ... to work very well with our Japanese side here," said Weber.
"I think when you transform a company, you need to understand where your starting point [is and] where you want to go, and also define the pace of change. Not too fast, not too slow," he said.
As for where Takeda stands on the path to turning business around, Weber said most of the foundation had already laid.
"We have done a lot on many fronts: on the commercial front, on the R&D, on the manufacturing. I will say that we have done the heavy lifting of the transformation and we are starting now to see the result, which is nice."